H.C. Wainwright downgraded Vigil Neuroscience (VIGL) to Neutral from Buy with a price target of $8, down from $14, after Sanofi (SNY) agreed to acquire Vigil for $470M upfront, with an additional $2 per share contingent on the commercial success of Vigil’s Alzheimer’s drug, VG-3927, with the deal expected to close in Q3. The firm cites the announced intended acquisition terms for the downgrade.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VIGL:
- Vigil Neuroscience Elects Directors at Annual Meeting
- Vigil Neuroscience downgraded to Neutral from Outperform at Mizuho
- Vigil Neuroscience downgraded to Hold from Buy at Jefferies
- Vigil Neuroscience downgraded to Neutral from Outperform at Wedbush
- Vigil Neuroscience Enters Merger Agreement with Sanofi